Leukemia Therapeutics Market to Rise at 8.1% CAGR till 2027; Industry Leaders Such as Pfizer and Bristol-Myers to Focus Investments on Advancing Clinical Trials: Fortune Business Insights™
According to a study conducted by the UK Coronavirus Cancer Monitoring Project (UKCCMP), patients with leukemia, multiple myeloma, and lymphoma are highly susceptible to COVID-19 and leukemia patients have twice the chance of dying from the virus. The study found that patients with blood cancer are 57% more likely to experience severe symptoms of COVID-19 than patients with other types of cancers. Given these and other similar findings, the demand for leukemia therapeutics has been soaring during the COVID-19 pandemic, with market players reporting increased sales. Bristol-Myers Squibb, for instance, announced that the sales of Sprycel, its treatment for chronic myeloid leukemia (CML) jumped 14% to USD 521 million in the first quarter of 2020. However, the disruption in the medical supply chain will lead the market to register a lower growth rate of 6.2% and touch a value of USD 16.15 billion in 2020.
Request a Sample Copy of the Research Report
As per the report findings, the estimated value of the global market stood at USD 15.21 billion in 2019. The main highlights of the report include:
Calculated estimations about the upcoming trends and prospects in the market;
Path-breaking research into the regional dynamics of the market;
Comprehensive study of the factors driving and restraining the market; and
Careful profiling and diagnosis of the key market players and their dominant strategies.
Debilitating Side Effects of Chemotherapy May Hinder Market Growth
Chemotherapy is one of the most potent leukemia therapeutics and has emerged as the most powerful and the most commonly recommended treatment for most types of cancers. Chemo drugs are designed to attack and kill fast-growing cells, and since cancer cells proliferate rapidly, these medications speedily eliminate them. However, because chemo medicines travel throughout the body, they end up killing healthy cells, leading to side effects that can considerably weaken the patient, albeit temporarily. For example, chemotherapy can harm the blood cells in the bone marrow, where red blood cells (RBCs) are manufactured. With RBC production disrupted, the patient is likely to experience moderate to severe anemia, which in turn can cause symptoms such as fatigue, lightheadedness, and general weakness. Furthermore, chemo can also harm the production of white blood cells (WBCs), the body’s soldiers that fight infections. As a result, cancer patients become extremely susceptible to infections and even a minor bout of cough & cold can prove detrimental for them. Thus, the known side effects of chemotherapy may hamper the leukemia therapeutics market growth.
Quick Buy Leukemia Therapeutics Market
An Overview of the Impact of COVID-19 on this Market:
The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.
We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.
The current pandemic of Covid-19 has made a catastrophic impact on the world. Most businesses are shut as a result of the increasing COVID-19 cases. The healthcare industry is facing shortage of medical aid as there are not enough beds to suffice the needs of the increasing number of patients. The world economy is fluctuating as most businesses are at a halt and the ones running from the vicinity of their homes are barely able to manage revenue.
Special reports on various markets affected by the coronavirus pandemic are provided by Fortune Business Insights. These reports will help visualize the current situation and what strategies can be adopted to help the market gain momentum in the coming years.
North America to Foster Stable Market Growth Backed by High Healthcare Expenditure
North America is expected to dominate the leukemia therapeutics market share during the forecast period as the USA and Canada have sharply increased their spending on healthcare technologies and infrastructure in the past few decades. Moreover, policymakers in the two countries are taking constant efforts to expand healthcare coverage, especially for cancer patients. In 2019, the region’s market size stood at USD 6.92 billion.
Europe is poised to emerge as the second-largest market for leukemia therapeutics due to the increasing number of leukemia patients in the continent. In the UK, for instance, leukemia accounted for 3% of all cancer cases in the country in 2017, according to Cancer Research UK. The market in Asia Pacific, on the other hand, will experience prolific growth owing to the improving health reimbursement policies in China and India.
Regulatory Support for Innovative Therapies to Raise Market Potential
Key players in this market are enjoying a period of consistent support for their offerings by regulatory bodies such as the US Food and Drug Administration (FDA). Such support will play an instrumental role in managing leukemia symptoms in patients and the criticality of leukemia therapeutics is likely to rise as cancer prevalence grows worldwide.
Have Any Query? Ask Our Experts
October 2020: The US FDA cleared AbbVie’s VENCLEXTA treatment in combination with azacitidine, or decitabine, or low-dose cytarabine. The therapy is indicated for treating acute myeloid leukemia (AML) in adults aged 75 years and above or those with comorbidities who cannot undergo intensive chemotherapy.
September 2020: Bristol Myers Squibb secured the US FDA’s approval for its Onuregfor the continued treatment of adult patients with AML. The treatment is designed for those patients who have attained the first complete remission or remission with incomplete blood recovery following intensive chemo.
List of Key Companies Covered in this Market Report:
Sanofi/ Genzyme Corporation (Paris, France)
Hoffmann-La Roche (Basel, Switzerland)
Johnson & Johnson Services, Inc. (New Brunswick, U.S.)
Amgen Inc. (Thousand Oaks, U.S.)
Novartis (Basel, Switzerland)
Takeda Pharmaceutical Co Ltd (Tokyo, Japan)
Bristol-Myers Squibb (New York, U.S.)
AbbVie (North Chicago, U.S.)
Lupin Ltd. (India, Mumbai)
Pfizer Inc. (New York, U.S.)
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune - 411045, Maharashtra, India.
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
LinkedIn | Twitter | Blogs
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Leukemia Therapeutics Market to Rise at 8.1% CAGR till 2027; Industry Leaders Such as Pfizer and Bristol-Myers to Focus Investments on Advancing Clinical Trials: Fortune Business Insights™ here
News-ID: 2374322 • Views: 150
More Releases from Fortune Business Insight
Global Aerostructure Market to Exhibit a CAGR of 4.07% from 2019-2026; Increasin …
The global aerostructures market will benefit from the increasing demand for improved and reliable aircraft structures across the world. According to a report published by Fortune Business Insights, titled “Aerostructure Market Size, Share & Industry Analysis, By Component (Wings, Nose, Fuselage, Nacelle, Empennage & Pylon and Others), By Material (Metals, Composites and Alloys), By Platform (Fixed-wing aircraft (Commercial Aircraft, Military Aircraft, and UAV’s) and Rotary-wing Aircraft (Commercial Aircraft, Military Aircraft,
Global Hospital Architecture Market to Show Remarkable Growth, Bolstered by Risi …
The increasing number of health issues and the need for better medical facilities are anticipated to create lucrative growth opportunities for the global hospital architecture market, finds Fortune Business Insights in their new study. The study is titled, “Hospital Architecture Market: Global Market Analysis, Insights, and Forecasts, 2019 – 2025.” Advanced Hospital Set-up Buildings to Promote Future Market Growth On account of various health issues prevalent around the world, the hospital architecture
Alpha-1 Antitrypsin Deficiency Treatment Market: Increasing Recommendations For …
The rising prevalence of “alpha-1 antitrypsin deficiency” is expected to aid growth of the global alpha-1 antitrypsin deficiency treatment market, says Fortune Business Insights in a report, titled “Alpha-1 Antitrypsin Deficiency Treatment Market Size, Share and Global Trend By Drug Class (Alpha-1 proteinase inhibitor, Bronchodilators, Steroids, Antibiotics), By Route of Administration (Oral, Injection, Inhalation), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Stores) and Geography Forecast till 2026.” The emerging
Sterilization Indicator Tape Market to Hit USD 171.5 Million in 2028; Usage of S …
The global sterilization indicator tape market is set to gain momentum from the rising usage of steam autoclaves for purifying surgical instruments, such as lancets, forceps, and scalpels. The National Center for Biotechnology Information declared that when used for 3-12 hours, chemicals, namely, hydrogen peroxide (7.5%), glutaraldehyde (≥2.4%), and peracetic acid (PAA) (0.2%) can sterilize instruments. As per a report by Fortune Business Insights™, titled, “Sterilization Indicator Tape Market, 2021-2028,”
More Releases for Leukemia
Global Leukemia Therapeutics Market Continued Growth Report
The “Global Leukemia Therapeutics Market Continued Growth Report” Latest added Leukemia Therapeutics Market research study by Zion Market Research offers detailed product outlook and elaborates market review till 2026. , The Leukemia Therapeutics Market is the most blooming and promising sector of the industry. This overall Leukemia Therapeutics Market has been ascending at a higher rate with the enhancement of inventive strategies and a raising customer tendency. The wide-coming to
Juvenile Myelomonocytic Leukemia Therapeutics- Pipeline Analysis 2018
Juvenile myelomonocytic leukemia is a rare disease that occurs mostly in the children who are under four years of age. The abnormal growth of the monocytes results in the accumulation of monocytes in the bone marrow. Download the sample report @ https://www.pharmaproff.com/request-sample/1116 This leads to improper functioning of the bone marrow. The actual cause of juvenile myelomonocytic leukemia is still unknown; however, mutation in the RAS gene is observed in patients
Acute Myeloid Leukemia Market Growth by 2021
Acute Myeloid Leukemia (AML) is classed as an orphans disease. AML is a rare but a severe disease and is a most common leukemia. It is primarily a disease of the elderly, with an average age of diagnosis of approximately 66. AML results from the acquired changes in the DNA of a developing marrow cell. The marrow cells get converted into the leukemic cells, multiplies into 11 billion or more.
Acute Leukemia Therapeutics Pipeline Analysis
Acute leukemia is also known as cancer of blood cells in which immature blood cells modify into cancer cells. The disease arises from bone marrow and causes formation of numerous large blood cells. Leukemia is categorized into five different types namely acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, and hairy cell leukemia. Leukemia can produce be symptoms such as fever, recurrent nosebleeds, bone pain, swollen
Leukemia Therapeutics Market – Global Industry Insights, 2025
Leukemia is a cancer of blood cells and therefore, are occasionally referred to as ‘blood cancer’. Most blood cells are formed in the bone marrow. In leukemia, undeveloped blood cells become cancer. Leukemia can be either acute or chronic. Acute leukemia is a fast growing cancer, which usually gets worse rapidly. Chronic leukemia is a slow growing cancer, which gets worse slowly over time period. The treatment and diagnosis of
New dynamics in monitoring diagnostics in leukemia
Dresden/Germany Diagnosis leukemia and stem cell transplantation The diagnosis "leukemia" for patients means to undergo several stressful therapeutic interventions. If chemotherapy is not effective, stem cell transplantation mostly is the last chance for healing. However, a sudden graft rejection or disease relapse can always occur despite the successful transfer of the hematopoietic stem cells from donor to recipient. Therefore, the regular quantitative assessment of the donor and recipient cell-portion in the blood